High-Grade Glioma Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Lantern Pharma, NeOnc Technologies, Merck Sharp & Dohme LLC, Regeneron Pharmaceu

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, High-Grade Glioma pipeline constitutes 150+ key companies continuously working towards developing 150+ High-Grade Glioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"High-Grade Glioma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the High-Grade Glioma Market.

The High-Grade Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the High-Grade Glioma Pipeline Report: https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel High-Grade Glioma treatment therapies with a considerable amount of success over the years.
• High-Grade Glioma companies working in the treatment market are Candel Therapeutics, Inc., PTC Therapeutics, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, Chimerix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals/S*Bio, PTC Therapeutics, Candel Therapeutics, OncoSynergy, and others, are developing therapies for the High-Grade Glioma treatment
• Emerging High-Grade Glioma therapies in the different phases of clinical trials are- CAN 3110, PTC596, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, ONC201, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, and others are expected to have a significant impact on the High-Grade Glioma market in the coming years.
• In January 2023, "ONC201 for the Treatment of Newly Diagnosed H3 K27Mmutant Diffuse Glioma Following Completion of Radiotherapy: A Randomised, Double-Blind, Placebo-Controlled, Multicenter Study" is the name of the trial that Chimerix started.
• In February 2023, According to Plus Therapeutics, the business is collaborating with the FDA on a planned Investigational New Drug (IND) application to treat young patients with high-grade gliomas and ependymomas.
• In January 2023, A clinical update from the ongoing Phase I trial investigating INB-200 in patients with newly diagnosed GBM was released by IN8bio, Inc., a clinical-stage biopharmaceutical firm researching novel gamma-delta T cell treatments, along with pipeline targets for 2023. In the first results from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM), all three patients outlived the median progression-free survival (PFS) of seven months, with two continued responses extending beyond 1.5 years and 1.2 years progression-free, respectively. Cohort 3 will be fully enrolled in the Phase I trial, and the business also intends to provide more data and topline outcomes with longer-term follow-up.
• In September 2022, CAN-2409 was given an orphan drug designation (ODD) by the European Medicines Agency (EMA) Committee for Orphan Medical Products for the purpose of treating glioma patients. In numerous ongoing clinical trials, CAN-2409 is being tested for high-grade gliomas, non-small cell lung cancer, pancreatic cancer, and prostate cancer.
• In August 2022, The US Food and Drug Administration (US FDA) has approved the investigational new drug application (IND) for JBI-778, an oral, brain penetrant, and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of primary brain tumours, including high-grade gliomas, as well as solid tumours with brain metastases.

High-Grade Glioma Overview
Glial cell tumours, which can develop in the brain and spinal cord, include high-grade gliomas. Because the tumours spread quickly through the brain tissue and grow quickly, they are referred to as "high-grade" tumours because they are challenging to cure. Children of all ages, from newborns to adults, get the tumours.

Get a Free Sample PDF Report to know more about High-Grade Glioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging High-Grade Glioma Drugs Under Different Phases of Clinical Development Include:
• CAN 3110: Candel Therapeutics, Inc.
• PTC596: PTC Therapeutics
• DSP 0390: Sumitomo Pharma Oncology, Inc.
• Terameprocol: Erimos Pharmaceuticals
• Lenvatinib: Eisai Inc.
• PVSRIPO: Istari Oncology, Inc.
• BMX-001: BioMimetix Pharma
• ONC201: Chimerix
• OKN-007: Oblato, Inc.
• Lisavanbulin: Basilea Pharmaceutica
• Terameprocol: Erimos Pharmaceuticals
• Zotiraciclib: Adastra Pharmaceuticals/S*Bio
• PTC596: PTC Therapeutics
• CAN-3110: Candel Therapeutics
• OS2966: OncoSynergy

High-Grade Glioma Route of Administration
High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

High-Grade Glioma Molecule Type
High-Grade Glioma Products have been categorized under various Molecule types, such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

High-Grade Glioma Pipeline Therapeutics Assessment
• High-Grade Glioma Assessment by Product Type
• High-Grade Glioma By Stage and Product Type
• High-Grade Glioma Assessment by Route of Administration
• High-Grade Glioma By Stage and Route of Administration
• High-Grade Glioma Assessment by Molecule Type
• High-Grade Glioma by Stage and Molecule Type

DelveInsight's High-Grade Glioma Report covers around 150+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further High-Grade Glioma product details are provided in the report. Download the High-Grade Glioma pipeline report to learn more about the emerging High-Grade Glioma therapies at:
https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the High-Grade Glioma Therapeutics Market include:
Key companies developing therapies for High-Grade Glioma are - Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee's Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, Istari Oncology, Angiochem, Epitopoietic Research Corporation, Oblato, Inc., Novartis, Candel Therapeutics, Chimerix, Onxeo SA, SonALAsense, Kintara Therapeutics, Kazia Therapeutics, VBI Vaccines, Lantern Pharma, NeOnc Technologies, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Cellectar Biosciences, OncoSynergy, Inc, WPD Pharmaceuticals, CellabMED, Alpheus Medical, Inc., Eli Lilly and Company, Xynomic Pharmaceuticals, Inc., Celldex Therapeutics, Sumitomo Pharma Oncology, Inc., Curis, Plus Therapeutics, and others.

High-Grade Glioma Pipeline Analysis:
The High-Grade Glioma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of High-Grade Glioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for High-Grade Glioma Treatment.
• High-Grade Glioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• High-Grade Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the High-Grade Glioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about High-Grade Glioma drugs and therapies-
https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

High-Grade Glioma Pipeline Market Drivers
• Increase in the prevalence of High Grade Glioma, increase in the accessibility to more options for the treatment and diagnosis of a high-grade tumor are some of the important factors that are fueling the High-Grade Glioma Market.

High-Grade Glioma Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the High-Grade Glioma Market growth.

Scope of High-Grade Glioma Pipeline Drug Insight
• Coverage: Global
• Key High-Grade Glioma Companies: Candel Therapeutics, Inc., PTC Therapeutics, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, Chimerix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals/S*Bio, PTC Therapeutics, Candel Therapeutics, OncoSynergy, and others
• Key High-Grade Glioma Therapies: CAN 3110, PTC596, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, ONC201, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, and others
• High-Grade Glioma Therapeutic Assessment: High-Grade Glioma current marketed and High-Grade Glioma emerging therapies
• High-Grade Glioma Market Dynamics: High-Grade Glioma market drivers and High-Grade Glioma market barriers

Request for Sample PDF Report for High-Grade Glioma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. High-Grade Glioma Report Introduction
2. High-Grade Glioma Executive Summary
3. High-Grade Glioma Overview
4. High-Grade Glioma- Analytical Perspective In-depth Commercial Assessment
5. High-Grade Glioma Pipeline Therapeutics
6. High-Grade Glioma Late Stage Products (Phase II/III)
7. High-Grade Glioma Mid Stage Products (Phase II)
8. High-Grade Glioma Early Stage Products (Phase I)
9. High-Grade Glioma Preclinical Stage Products
10. High-Grade Glioma Therapeutics Assessment
11. High-Grade Glioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. High-Grade Glioma Key Companies
14. High-Grade Glioma Key Products
15. High-Grade Glioma Unmet Needs
16 . High-Grade Glioma Market Drivers and Barriers
17. High-Grade Glioma Future Perspectives and Conclusion
18. High-Grade Glioma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

High-Grade Glioma Market https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'High-Grade Glioma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

High-Grade Glioma Epidemiology https://www.delveinsight.com/report-store/high-grade-glioma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'High-Grade Glioma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.